Published in Women's Health Weekly, March 5th, 2009
Paul A. Friedman, M.D., Incyte’s President and Chief Executive Officer, stated: “We made significant clinical progress in 2008 including the submission of a Special Protocol Assessment to the FDA for our lead JAK inhibitor, INCB18424, as a treatment for myelofibrosis. As expected, the FDA has made suggestions regarding the proposed protocol to which we plan to respond within the next few weeks. If the FDA agrees with our response we would remain on track to begin our Phase III program in the first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.